²¹¹At-NaAt (²¹¹At-Sodium Astatide) is the Astatine labeled analogue of the marketed ¹³¹I-Sodium Iodide (¹³¹I-NaI), the standard diagnostic and therapeutic agent for diseases affecting the thyroid, including carcinomas, first radiotherapeutic invented in 1941, and standard therapeutic since the beginning of the 1950s. It is under development at the Osaka university hospital and has entered Phase I/II trial.

Target/Mechanism: Thyroid tissues

Carrier/Ligand: n/a

Radiation Type : beta electrons (β^–)